Celltrion to Present New Analyses of ZYMFENTRA® (infliximab-dyyb) in Crohn's Disease and Ulcerative Colitis at ACG 2026

Celltrion to Present New Analyses of ZYMFENTRA® (infliximab-dyyb) in Crohn's Disease and Ulcerative Colitis at ACG 2026

New data show favorable outcomes with subcutaneous infliximab following intravenous infliximab interruption, regardless of prior antibody status, in adult patients with moderate to severely active Crohn's disease and ulcerative colitisLate-breaking analysis shows significantly higher rates of clinical remission and improved…

Celltrion presents Zymfentra clinical data at gastroenterology meeting

Biopharmaceutical firm Celltrion USA scheduled two oral presentations evaluating Zymfentra in Crohn's disease and ulcerative colitis at the American College of Gastroenterology conference.